A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Lilly

Status and phase: Not yet enrolling; Phase 1

Conditions: Overweight; Obesity

Treatments: Drug: LY4174794; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07654972

27797

J6W-MC-YMAA (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.

Participation in this study will last about 35 to 45 weeks (7 to 11 months).

Enrollment: 108 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
• Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
• Have had a self-reported stable weight for 3 months prior to screening

Exclusion criteria

• Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
• Is an individual of childbearing potential (IOCBP)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Double Blind

---

108 participants in 4 patient groups, including a placebo group

Part A: LY4174794

Experimental group

Description:

Participants will receive LY4174794 administered subcutaneously (SC).

Treatment:

Drug: LY4174794

Drug: Placebo

Drug: LY4174794

Part B: LY4174794

Experimental group

Description:

Participants will receive LY4174794 administered SC.

Treatment:

Drug: LY4174794

Drug: Placebo

Drug: LY4174794

Part A & B: Placebo

Placebo Comparator group

Description:

Participants will receive placebo administered SC.

Treatment:

Drug: Placebo

Part C: LY4174794

Experimental group

Description:

Participants will receive LY4174794 administered intravenously (IV).

Treatment:

Drug: LY4174794

Drug: LY4174794